Exogenous cholecystokinin selectively antagonizes opiate analgesia, which suggests that endogenous cholecystokinin may act physiologically as an opiate antagonist and may play a role in opiate tolerance. The use of the selective cholecystokinin antagonist proglumide provided a test of these hypotheses in rats that were either inexperienced with or tolerant to opiates. Proglumide potentiated ana...

Intracisternally administered cholecystokinin produced long lasting hypothermia in mice, and the hypothermic effect was significantly antagonized by benzodiazepines like chlordiazepoxide and diazepam and by a benzodiazepine antagonist, Ro 15-1788, that were administered intraperitoneally. Proglumide, a cholecystokinin antagonist, failed to prevent the hypothermia induced by cholecystokinin at a...

The fermentation and isolation of a new, non-peptide cholecystokinin antagonist, asperlicin, produced by Aspergillus alliaceus is described. The potent and specific interaction of asperlicin with cholecystokinin receptors was shown using in vitro biochemical assays.

the effects of cholecystokinin (cck) receptor antagonists on hypothermia induced by cocaine or morphine have been studied in mice. in the present work, subcutaneous (sc) injection of cocaine (50-150 mg/kg) or morphine (125-500 mg/kg) induced hypothermia in mice. administration of ccka receptor antagonist mk-329 (0.5-1.5 mg/kg), cckb receptor antagonist l-365, 260 (0.5-1.5 mgl kg) and cck recept...

The effects of cholecystokinin (CCK) receptor antagonists on hypothermia induced by cocaine or morphine have been studied in mice. In the present work, subcutaneous (SC) injection of cocaine (50-150 mg/kg) or morphine (125-500 mg/kg) induced hypothermia in mice. Administration of CCKA receptor antagonist MK-329 (0.5-1.5 mg/kg), CCKB receptor antagonist L-365, 260 (0.5-1.5 mgl kg) and CCK r...

Receptor-mediated endocytosis has been observed after agonist occupation of several G protein-coupled receptors, which contributes to the desensitization response to agonist stimulation; however, the cellular signals required to initiate this process are unclear. In this study, we developed and characterized a new antagonist analogue of cholecystokinin (D-Tyr-Gly-[(Nle28,31,D-Trp30)cholecystoki...

The effects of cholecystokinin receptor antagonist, dipentyl-3,4-dichloroproglumide (DDP), on stimulated pancreatic and gastric secretion were studied in the rat. DDP dose-dependently inhibited cholecystokinin-stimulated amylase release from dispersed acinar cells. In vivo, DDP inhibited cholecystokinin octapeptide-stimulated amylase and protein secretion. DDP also inhibited pentagastrin-stimul...

Pentobarbital administered intracerebroventricularly to mice has been shown previously to inhibit the analgesic action of morphine given intrathecally. The purpose of the present study was to examine the proposal that this antianalgesic action was mediated spinally by cholecystokinin. First, intrathecal coadministration of cholecystokinin-B sulfate (CCK8s) with morphine inhibited the analgesic ...

s directly related to the thesis 1. Kapás, L., F. Obál, Jr., P. Alföldi, G. Rubicsek, B. Penke, and F. Obál. Sleep elicited by peripheral injection of cholecystokinin in rats. Neuroscience 22: p. S841, 1987. 2. Kapás, L., M. R. Opp, L. Johannsen, and J. M. Krueger. Divergent effects of central and peripheral injections of cholecystokinin (CCK) on sleep-wake activity in rabbits. Sleep Res. 19: p...